Market Closed -
Nasdaq Copenhagen
10:59:59 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
130
DKK
|
+4.50%
|
|
+3.50%
|
+28.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
17,801
|
27,291
|
37,650
|
21,222
|
22,384
|
28,755
|
-
|
-
|
Enterprise Value (EV)
1 |
18,475
|
27,697
|
37,922
|
21,430
|
22,374
|
28,390
|
27,716
|
26,609
|
P/E ratio
|
-356
x
|
1,101
x
|
173
x
|
63.6
x
|
46
x
|
36.9
x
|
27.4
x
|
22.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.44
x
|
7.82
x
|
9.61
x
|
4.7
x
|
4.64
x
|
5.37
x
|
4.87
x
|
4.44
x
|
EV / Revenue
|
5.64
x
|
7.93
x
|
9.68
x
|
4.75
x
|
4.64
x
|
5.31
x
|
4.69
x
|
4.1
x
|
EV / EBITDA
|
76.7
x
|
70.1
x
|
71
x
|
30.3
x
|
24.6
x
|
22.3
x
|
16.5
x
|
13.8
x
|
EV / FCF
|
-739
x
|
495
x
|
188
x
|
330
x
|
76.6
x
|
83.3
x
|
32.4
x
|
24.8
x
|
FCF Yield
|
-0.14%
|
0.2%
|
0.53%
|
0.3%
|
1.31%
|
1.2%
|
3.08%
|
4.03%
|
Price to Book
|
5.74
x
|
8.83
x
|
11
x
|
5.34
x
|
5.06
x
|
5.54
x
|
4.6
x
|
3.83
x
|
Nbr of stocks (in thousands)
|
217,745
|
218,327
|
219,534
|
220,946
|
221,189
|
221,189
|
-
|
-
|
Reference price
2 |
81.75
|
125.0
|
171.5
|
96.05
|
101.2
|
130.0
|
130.0
|
130.0
|
Announcement Date
|
2/5/20
|
2/10/21
|
2/8/22
|
2/3/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3,274
|
3,491
|
3,916
|
4,511
|
4,824
|
5,350
|
5,907
|
6,483
|
EBITDA
1 |
241
|
395
|
534
|
708
|
911
|
1,274
|
1,679
|
1,930
|
EBIT
1 |
-14
|
150
|
292
|
470
|
666
|
1,005
|
1,391
|
1,648
|
Operating Margin
|
-0.43%
|
4.3%
|
7.46%
|
10.42%
|
13.81%
|
18.79%
|
23.55%
|
25.42%
|
Earnings before Tax (EBT)
1 |
-31
|
101
|
279
|
447
|
647
|
994.2
|
1,379
|
1,647
|
Net income
1 |
-50
|
25
|
219
|
335
|
486
|
759.9
|
1,058
|
1,275
|
Net margin
|
-1.53%
|
0.72%
|
5.59%
|
7.43%
|
10.07%
|
14.2%
|
17.91%
|
19.67%
|
EPS
2 |
-0.2295
|
0.1135
|
0.9900
|
1.510
|
2.200
|
3.522
|
4.753
|
5.741
|
Free Cash Flow
1 |
-25
|
56
|
202
|
65
|
292
|
341
|
855
|
1,073
|
FCF margin
|
-0.76%
|
1.6%
|
5.16%
|
1.44%
|
6.05%
|
6.37%
|
14.47%
|
16.56%
|
FCF Conversion (EBITDA)
|
-
|
14.18%
|
37.83%
|
9.18%
|
32.05%
|
26.77%
|
50.92%
|
55.61%
|
FCF Conversion (Net income)
|
-
|
224%
|
92.24%
|
19.4%
|
60.08%
|
44.87%
|
80.84%
|
84.18%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/5/20
|
2/10/21
|
2/8/22
|
2/3/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
928
|
1,099
|
1,155
|
1,045
|
1,062
|
1,249
|
1,234
|
1,135
|
1,110
|
1,345
|
1,353
|
1,246
|
1,237
|
1,516
|
EBITDA
1 |
124
|
136
|
272
|
107
|
128
|
201
|
288
|
157
|
208
|
258
|
359.5
|
235
|
289
|
405.5
|
EBIT
1 |
55
|
79
|
215
|
49
|
68
|
138
|
228
|
97
|
147
|
194
|
289
|
163.5
|
218.5
|
335
|
Operating Margin
|
5.93%
|
7.19%
|
18.61%
|
4.69%
|
6.4%
|
11.05%
|
18.48%
|
8.55%
|
13.24%
|
14.42%
|
21.36%
|
13.12%
|
17.66%
|
22.09%
|
Earnings before Tax (EBT)
1 |
54
|
74
|
217
|
56
|
70
|
104
|
217
|
89
|
155
|
186
|
291
|
147
|
206
|
317
|
Net income
1 |
37
|
76
|
163
|
42
|
52
|
78
|
163
|
66
|
117
|
140
|
214.5
|
120
|
160.9
|
249.5
|
Net margin
|
3.99%
|
6.92%
|
14.11%
|
4.02%
|
4.9%
|
6.24%
|
13.21%
|
5.81%
|
10.54%
|
10.41%
|
15.85%
|
9.63%
|
13.01%
|
16.45%
|
EPS
2 |
0.1700
|
0.3450
|
0.7400
|
0.1900
|
0.2300
|
0.3500
|
0.7000
|
0.3000
|
0.5000
|
0.7000
|
0.9650
|
0.5350
|
0.7200
|
1.130
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
2/8/22
|
5/12/22
|
8/11/22
|
11/10/22
|
2/3/23
|
5/9/23
|
8/24/23
|
11/15/23
|
2/8/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
674
|
406
|
272
|
208
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
10
|
364
|
1,039
|
2,146
|
Leverage (Debt/EBITDA)
|
2.797
x
|
1.028
x
|
0.5094
x
|
0.2938
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-25
|
56
|
202
|
65
|
292
|
341
|
855
|
1,073
|
ROE (net income / shareholders' equity)
|
-1.6%
|
0.8%
|
6.6%
|
9%
|
11.5%
|
15.8%
|
18.4%
|
18.2%
|
ROA (Net income/ Total Assets)
|
-0.97%
|
0.45%
|
3.84%
|
5.52%
|
7.46%
|
10.8%
|
13.3%
|
13.7%
|
Assets
1 |
5,181
|
5,529
|
5,696
|
6,069
|
6,517
|
7,044
|
7,965
|
9,291
|
Book Value Per Share
2 |
14.30
|
14.20
|
15.60
|
18.00
|
20.00
|
23.50
|
28.30
|
33.90
|
Cash Flow per Share
2 |
0.6100
|
1.380
|
2.140
|
1.900
|
3.000
|
3.500
|
5.500
|
6.100
|
Capex
1 |
147
|
196
|
263
|
353
|
379
|
380
|
377
|
402
|
Capex / Sales
|
4.49%
|
5.61%
|
6.72%
|
7.83%
|
7.86%
|
7.1%
|
6.39%
|
6.2%
|
Announcement Date
|
2/5/20
|
2/10/21
|
2/8/22
|
2/3/23
|
2/8/24
|
-
|
-
|
-
|
Average target price
132.8
DKK Spread / Average Target +2.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +28.46% | 4.12B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|